Change in Phase III clinical study design for OBI-822 targeting TNBC and will continue the study with new clinical study design

1.Date of occurrence of the event: Jul 22, 2020 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4.Reciprocal shareholding ratios: No applicable 5.Cause of occurrence: Active cancer immunotherapy OBI-822 (Adagloxad Simolenin) targets patients of triple negative breast cancer (TNBC) with high Globo H expression. The global Phase […]

This article is password protected.

To view the content, please enter your password in the field below